Novel mutations of KRAS in patients with Noonan syndrome spectrum disorders. Partial alignment of human K‐RasA, K‐RasB, N‐Ras, H‐RasA and H‐RasB is shown. Mutated amino acid residues presented in this study are indicated in green, those altered in previously reported patients (but not present in our study cohort) in blue and residues G12, G13 and Q61, which are most commonly found to be mutated in tumours, in red. Clinical photographs document the variable craniofacial phenotype of patients with heterozygous KRAS mutations (second panel from top and bottom panel). Arrows point from the patients' photographs to the respective residues mutated in K‐Ras. The patient's number (according to table 1) is given in the upper left corner of each photograph. Additional photographs documenting deep palms of patient Nos 1 and 12 as well as earlier photographs of patient Nos 2, 3, 5 and 7 are shown in the top row. We obtained written consent from the patient or his/her legal guardian for publication of the images.